000 | 02010 a2200517 4500 | ||
---|---|---|---|
005 | 20250515162517.0 | ||
264 | 0 | _c20090416 | |
008 | 200904s 0 0 eng d | ||
022 | _a1078-0432 | ||
024 | 7 |
_a10.1158/1078-0432.CCR-08-1535 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aDuiker, Evelien W | |
245 | 0 | 0 |
_aEnhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. _h[electronic resource] |
260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cMar 2009 |
||
300 |
_a2048-57 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
650 | 0 | 4 |
_aCaspase 3 _xmetabolism |
650 | 0 | 4 | _aCell Line, Tumor |
650 | 0 | 4 |
_aCisplatin _xpharmacology |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aLuminescent Measurements |
650 | 0 | 4 | _aMice |
650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
650 | 0 | 4 |
_aReceptors, TNF-Related Apoptosis-Inducing Ligand _xmetabolism |
650 | 0 | 4 |
_aRecombinant Proteins _xpharmacology |
650 | 0 | 4 |
_aTNF-Related Apoptosis-Inducing Ligand _xpharmacokinetics |
650 | 0 | 4 | _aTissue Distribution |
650 | 0 | 4 | _aXenograft Model Antitumor Assays |
700 | 1 | _ade Vries, Elisabeth G E | |
700 | 1 | _aMahalingam, Devalingam | |
700 | 1 | _aMeersma, Gert Jan | |
700 | 1 | _aBoersma-van Ek, Wytske | |
700 | 1 | _aHollema, Harry | |
700 | 1 | _aLub-de Hooge, Marjolijn N | |
700 | 1 | _avan Dam, Go M | |
700 | 1 | _aCool, Robbert H | |
700 | 1 | _aQuax, Wim J | |
700 | 1 | _aSamali, Afshin | |
700 | 1 | _avan der Zee, Ate G J | |
700 | 1 | _ade Jong, Steven | |
773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 15 _gno. 6 _gp. 2048-57 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-08-1535 _zAvailable from publisher's website |
999 |
_c18716022 _d18716022 |